• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy.

作者信息

Phillips William J, Camidge D Ross, Wheatley-Price Paul

机构信息

Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.

Department of Medicine, University of Colorado Cancer Center, Aurora, Colorado.

出版信息

J Thorac Oncol. 2025 Jan;20(1):30-33. doi: 10.1016/j.jtho.2024.10.010.

DOI:10.1016/j.jtho.2024.10.010
PMID:39794103
Abstract
摘要

相似文献

1
Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy.新辅助化疗免疫治疗后达到病理完全缓解的患者不应使用辅助免疫治疗。
J Thorac Oncol. 2025 Jan;20(1):30-33. doi: 10.1016/j.jtho.2024.10.010.
2
Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report.新辅助化疗免疫治疗后可切除非小细胞肺癌患者辅助免疫治疗的预后影响：简要报告
JTO Clin Res Rep. 2024 Nov 12;6(1):100763. doi: 10.1016/j.jtocrr.2024.100763. eCollection 2025 Jan.
3
Neoadjuvant vs Adjuvant Chemoimmunotherapy for Stage II-IIIB Non-Small Cell Lung Cancer.新辅助与辅助化疗免疫治疗 II-IIIB 期非小细胞肺癌。
Ann Thorac Surg. 2024 Sep;118(3):672-681. doi: 10.1016/j.athoracsur.2024.01.004. Epub 2024 Jan 28.
4
Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-Analysis.新辅助化疗免疫治疗后可切除非小细胞肺癌患者完全或主要病理缓解后的无事件生存期改善，无论辅助治疗如何：一项系统评价和个体患者数据荟萃分析
J Thorac Oncol. 2025 Mar;20(3):285-295. doi: 10.1016/j.jtho.2024.09.1443. Epub 2024 Oct 9.
5
Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited-stage small-cell lung cancer.新辅助化免疫治疗原发性局限期小细胞肺癌的病理反应。
Thorac Cancer. 2022 Nov;13(22):3208-3216. doi: 10.1111/1759-7714.14679. Epub 2022 Oct 8.
6
Non-invasive prediction for pathologic complete response to neoadjuvant chemoimmunotherapy in lung cancer using CT-based deep learning: a multicenter study.基于 CT 的深度学习在肺癌新辅助化疗免疫治疗病理完全缓解中的无创预测：一项多中心研究。
Front Immunol. 2024 Mar 25;15:1327779. doi: 10.3389/fimmu.2024.1327779. eCollection 2024.
7
Outcomes of Resectable Locally Advanced Non-Small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy: A Single Institution Experience.新辅助化疗免疫治疗后可切除的局部晚期非小细胞肺癌的疗效：单机构经验
J Clin Med. 2025 Feb 4;14(3):988. doi: 10.3390/jcm14030988.
8
Major pathologic response as a prognostic surrogate in esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy/chemoimmunotherapy: A multi-center cohort study.主要病理反应作为接受新辅助化疗/化疗免疫治疗的食管鳞状细胞癌患者的预后替代指标：一项多中心队列研究。
Eur J Surg Oncol. 2025 Feb;51(2):109500. doi: 10.1016/j.ejso.2024.109500. Epub 2024 Nov 24.
9
Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis.非小细胞肺癌的新辅助免疫治疗或化疗免疫治疗：一项系统评价和荟萃分析
Transl Lung Cancer Res. 2022 Feb;11(2):277-294. doi: 10.21037/tlcr-22-75.
10
[Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC].新辅助化疗免疫疗法在可切除非小细胞肺癌中的应用
Zhongguo Fei Ai Za Zhi. 2023 Nov 20;26(11):822-832. doi: 10.3779/j.issn.1009-3419.2023.102.40.

引用本文的文献

1
Efficacy of adjuvant therapy regimens administered during the perioperative period in resectable non-small cell lung cancer.可切除非小细胞肺癌围手术期辅助治疗方案的疗效
Cancer Immunol Immunother. 2025 Sep 1;74(9):296. doi: 10.1007/s00262-025-04159-0.
2
Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study.可切除的 III 期非小细胞肺癌患者在新辅助化疗免疫治疗后辅助免疫治疗是否必要？一项双中心真实世界研究。
Cancer Immunol Immunother. 2025 Jul 21;74(8):273. doi: 10.1007/s00262-025-04130-z.
3
Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy.
免疫治疗时代非小细胞肺癌的围手术期管理
Cells. 2025 Jun 25;14(13):971. doi: 10.3390/cells14130971.